<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="213554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306176</url>
  </required_header>
  <id_info>
    <org_study_id>1975</org_study_id>
    <nct_id>NCT00306176</nct_id>
  </id_info>
  <brief_title>Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate the influence of systemic exercise,
      rosiglitazone administration and combined pharmaceutical and lifestyle intervention on
      cardiovascular risk factors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular risk factors alterations</measure>
  </primary_outcome>
  <enrollment>100</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II diabetes mellitus

          -  Poor glycemic control

        Exclusion Criteria:

          -  Heart failure

          -  Renal disease

          -  Liver disease

          -  Cardiovascular event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos Liapis, PhD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Athens,Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHEPA University Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <lastchanged_date>April 3, 2007</lastchanged_date>
  <firstreceived_date>March 22, 2006</firstreceived_date>
  <keyword>rosiglitazone,exercise,cardiovascular risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
